+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Osteosarcoma - Pipeline Review, H1 2017

  • ID: 4189125
  • Report
  • March 2017
  • 255 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advaxis Inc
  • Bayer AG
  • CytRx Corp
  • Isofol Medical AB
  • MD Biosciences GmbH
  • Merck KGaA
  • MORE
Osteosarcoma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 7, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Advaxis Inc
  • Bayer AG
  • CytRx Corp
  • Isofol Medical AB
  • MD Biosciences GmbH
  • Merck KGaA
  • MORE
Introduction

Osteosarcoma - Overview

Osteosarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Osteosarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteosarcoma - Companies Involved in Therapeutics Development

Advaxis Inc

Allosteros Therapeutics Inc

Amgen Inc

AVEO Pharmaceuticals Inc

Bayer AG

Bellicum Pharmaceuticals Inc

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

CorMedix Inc

CytRx Corp

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Intezyne Technologies Inc

Isofol Medical AB

Johnson & Johnson

MacroGenics Inc

MD Biosciences GmbH

MediaPharma srl

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Novartis AG

Oncolys BioPharma Inc

Pfizer Inc

Shionogi & Co Ltd

Teijin Pharma Ltd

United Therapeutics Corp

Osteosarcoma - Drug Profiles

3D-QM - Drug Profile

3D-QMS - Drug Profile

ADXS-HER2 - Drug Profile

aldoxorubicin hydrochloride - Drug Profile

AM-7209 - Drug Profile

AU-101 - Drug Profile

AV-203 - Drug Profile

avelumab - Drug Profile

axitinib - Drug Profile

Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile

Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile

Celyvir - Drug Profile

cisplatin SR - Drug Profile

daunorubicin hydrochloride - Drug Profile

dihydroartemisinin - Drug Profile

dinutuximab - Drug Profile

enoblituzumab - Drug Profile

everolimus - Drug Profile

glembatumumab vedotin - Drug Profile

ipilimumab + nivolumab - Drug Profile

irinotecan hydrochloride - Drug Profile

IT-139 - Drug Profile

JNJ-64457107 - Drug Profile

lenvatinib mesylate - Drug Profile

ligerin - Drug Profile

MD-401A - Drug Profile

Modufolin - Drug Profile

Monoclonal Antibody for Osteosarcoma - Drug Profile

Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile

MPE-8.3 - Drug Profile

NT-157 - Drug Profile

OBP-702 - Drug Profile

Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile

pazopanib hydrochloride - Drug Profile

pembrolizumab - Drug Profile

Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile

radium Ra 223 dichloride - Drug Profile

RSF-101 - Drug Profile

S-588410 - Drug Profile

SEN-461 - Drug Profile

Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile

Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile

taurolidine - Drug Profile

Vaccine for Osteosarcoma - Drug Profile

VIMO-001 - Drug Profile

Osteosarcoma - Dormant Projects

Osteosarcoma - Discontinued Products

Osteosarcoma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Osteosarcoma, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Osteosarcoma - Pipeline by Advaxis Inc, H1

Osteosarcoma - Pipeline by Allosteros Therapeutics Inc, H1

Osteosarcoma - Pipeline by Amgen Inc, H1

Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H1

Osteosarcoma - Pipeline by Bayer AG, H1

Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H1

Osteosarcoma - Pipeline by Bristol-Myers Squibb Company, H1

Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H1

Osteosarcoma - Pipeline by CorMedix Inc, H1

Osteosarcoma - Pipeline by CytRx Corp, H1

Osteosarcoma - Pipeline by Eisai Co Ltd, H1

Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H1

Osteosarcoma - Pipeline by Intezyne Technologies Inc, H1

Osteosarcoma - Pipeline by Isofol Medical AB, H1

Osteosarcoma - Pipeline by Johnson & Johnson, H1

Osteosarcoma - Pipeline by MacroGenics Inc, H1

Osteosarcoma - Pipeline by MD Biosciences GmbH, H1

Osteosarcoma - Pipeline by MediaPharma srl, H1

Osteosarcoma - Pipeline by Merck & Co Inc, H1

Osteosarcoma - Pipeline by Merck KGaA, H1

Osteosarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1

Osteosarcoma - Pipeline by Novartis AG, H1

Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H1

Osteosarcoma - Pipeline by Pfizer Inc, H1

Osteosarcoma - Pipeline by Shionogi & Co Ltd, H1

Osteosarcoma - Pipeline by Teijin Pharma Ltd, H1

Osteosarcoma - Pipeline by United Therapeutics Corp, H1

Osteosarcoma - Dormant Projects, H1

Osteosarcoma - Discontinued Products, H1

List of Figures:

Number of Products under Development for Osteosarcoma, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
4 of 5
  • Advaxis Inc
  • Allosteros Therapeutics Inc
  • Amgen Inc
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics Inc
  • CorMedix Inc
  • CytRx Corp
  • Eisai Co Ltd
  • Eleison Pharmaceuticals LLC
  • Intezyne Technologies Inc
  • Isofol Medical AB
  • Johnson & Johnson
  • MacroGenics Inc
  • MD Biosciences GmbH
  • MediaPharma srl
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Novartis AG
  • Oncolys BioPharma Inc
  • Pfizer Inc
  • Shionogi & Co Ltd
  • Teijin Pharma Ltd
  • United Therapeutics Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll